Aftermarket
Check out the latest Medtech news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
News
ASX Rebalance: Tech in, lithium out of S&P/ASX 200 as uranium stocks enter S&P/ASX 300
Experts
Dr Boreham’s Crucible: Don’t have a heart attack, CSL’s profit-making ability is in the blood
Health & Biotech
Dr Boreham’s Crucible: ResMed holders breathe easy – those fat-busting needles have only hurt a little bit
Stockhead TV
What’s in store for 2024: Optiscan
Tech
Stock Insiders: Optiscan is expanding and the potential is enormous
Health & Biotech
Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX
Health & Biotech
Allegra’s game-changing Spinal Cage device awaits FDA nod, as ASX medical device stocks make inroads
Tech
Optiscan’s platform could address global pathologist shortage
News
Closing Bell: Friday takes a bite out of ASX, even as biotech and lithium small caps run amok
Tech
‘Take advantage of market consolidation’: EYE ready for proposed US Medicare changes
Health & Biotech
‘Diagnose on the spot’: Optiscan’s platform brings together surgeons and pathologists for better cancer outcomes
Health & Biotech
Curvebeam AI CEO says medical devices beat drugs to revenue, massive market in medical imaging
Health & Biotech
MDMA and magic mushrooms have arrived: Australia lets psychs find a new way for happy to fight sad
News
Rise and Shine: Everything you need to know about the day ahead
News
Top 10 at 10: Microcap biotech Imagion up 33pc after achieving enrolment target for Phase 1 trial
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Health & Biotech
Stock Insiders: Nova Eye Medical surges 20pc after FDA clears glaucoma treatment
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Health Kick Podcast: Aussie Bio Tech Medlab is confident in highly anticipated Phase III trial
Health & Biotech
CardieX Raises $4.5 million as it gears up for dual US listing as CONNEQT Pulse awaits FDA Clearance
Stockhead TV
2023 Prepped and Primed: Opyl (ASX:OPL) with CEO, Michelle Gallaher
Experts
Tim Boreham’s 20 ASX stocks that are primed to run in 2023 – Part 2
Stockhead TV
Year in Review: Opyl (ASX:OPL) with CEO, Michelle Gallaher
Health & Biotech
Opyl’s TrialKey achieves major milestone with potential to improve clinical trial success rates
Experts
Innovation never sleeps: Franklin Templeton says watch these 5 big tech shifts this quarter
Health & Biotech
Opyl tips revenue growth from partnership with Consentic and its newly launched screening services
Investor Guides
Investor Guide: Health & Biotech FY2023
Stockhead TV
CAR-T therapies are leading the race to cure cancer
Health & Biotech
Opyl appoints news chairman as it eyes international growth
Health & Biotech
Opyl prepares to launch Opin into the global $4.7 billion clinical trial recruitment market
Escrow Watch
ASX Escrow Watch: Spring is in the air and so is the season for releasing shares
Health & Biotech
CardieX pumped up with insto support for $4.33 million raise – announces additional purchase plan for shareholders
News
ASX Small Caps Lunch Wrap: Who’s making an unlikely political tilt today?
Health & Biotech
Health Kick Podcast: How Osteopore is innovating in the area of bone and tissue regeneration
Health & Biotech
Stock Insiders: MGC Pharmaceuticals’ ‘golden blanket’ combines multiple elements for better patient efficacy
Stockhead TV
V-Con: Small Cap Showcase Part 2 – Finding strong companies in a weak market
Health & Biotech
Leading Aussie medtechs Osteopore and Singular Health reveal landmark deal
Experts
MoneyTalks: Get your portfolio in rude health with these 3 ASX life science stocks
Tech
Best results yet: Audeara smashes quarterly sales records, up 175% PCP
Tech
Global retail deal with Amplifon has Audeara shouting from on top of the world
Health & Biotech
Opyl joins forces with two key patient advocate groups
Health & Biotech
Cast your eyes over these 15 weird and wonderful biotech stocks we found on the ASX
Experts
ScoPo’s Powerplays: ASX health stocks offer bargains galore during tax time sell down
Experts
ScoPo’s Powerplays: Who stands out in the enterprise imaging sector?
Health & Biotech
Primed for growth: Audeara increases sales channels by 20% by partnering with optometry giant Specsavers
Health & Biotech
Stock Insiders: NGS are reaching new heights with a clinically tested nutritional supplement
Health & Biotech
Dr Boreham’s Crucible: Picture this – a growth stock that makes money, pays divvies and accrues cash
Load More